Sanofi’s mRNA COVID-19 vaccine candidate not ready this year, CEO says By Reuters – Investing.com

PARIS (Reuters) – A COVID-19 vaccine candidate developed by Sanofi (NASDAQ:SNY) and U.S. group Translate Bio (NASDAQ:TBIO) “will not be ready this year,” the French drugmaker’s chief executive told Le Journal du Dimanche newspaper.
Clinical trials of this vaccine, which will be based on a technology known as mRNA — on which lean approved vaccines of Pfizer/BioNTech and Moderna (NASDAQ:MRNA) –, are expected to start this quarter.
In December last year, Sanofi had said it was targeting “earliest…

Click here to view the original article.